部分凝血活酶时间
比伐卢定
聚己内酯
生物医学工程
凝血酶时间
肝素
凝血活酶
材料科学
血栓形成
体内
凝血酶原时间
化学
凝结
药理学
医学
血栓形成
外科
心脏病学
内科学
生物
聚合物
心肌梗塞
复合材料
生物技术
经皮冠状动脉介入治疗
作者
Qiqi Sun,Jianghua Si,Lili Zhao,Tingting Wei,Ting Wang,Feiyi Li,Yang Li,Muhammad Shafiq,Lili Wang,Ruihua Liu,Dengke Zhi,Kai Wang
标识
DOI:10.1016/j.compositesb.2022.109702
摘要
Synthetic artificial vascular grafts are hampered by their low patency rate in substituting small-caliber arteries (inner diameter <6 mm) because of their poor hemocompatibility. As compared to the heparin, bivalirudin (BV), a direct thrombin inhibitor, is a more reliable anticoagulant. In this study, BV-loaded polycaprolactone (PCL) grafts (PCL-BV) were fabricated by electrospinning. The loading rate of BV was approximately 87%. The PCL-BV grafts achieved the sustained release of BV for up to 30 days in vitro, but mainly released in the first 15 days. Scanning electron microscopy (SEM) and mechanical testing revealed that the BV loading did not affect the structure and mechanical properties of PCL grafts. In vitro coagulation analysis showed that the loading of the BV reduced thrombin activity, prolonged hemocompatibility parameters (activated partial thromboplastin time (APTT), prothrombin time (PT) and thromboplastin time (TT)), reduced blood coagulation, and inhibited the adhesion and activation of fibrinogen (FIB) and platelets. The assessment of vascular grafts in a rabbit arteriovenous (AV)-shunt ex vitro and carotid artery implantation in vivo indicated that BV significantly improved the antithrombogenicity and patency of PCL grafts. Overall, these results suggested that the incorporation of BV into electrospun grafts would be an effective approach to improve the hemocompatibility and patency rate of synthetic vascular grafts.
科研通智能强力驱动
Strongly Powered by AbleSci AI